Br J Clin Pharmacol 1999; 48: 402-408.
‘Genetic polymorphism of S-mephenytoin 4′-hydroxylation in populations of African descent.’
H. G. Xie, R. B. Kim, C. M. Stein, G. R. Wilkinson & A. J. J. Wood
p. 403 The last sentence of paragraph 2 of Methods should read ‘these single-point mutations remove respectively, restriction endonucleases BamH1 and Sma1 sites [5, 6, 10, 18–21, 27–30].
p. 406 In the first line of the left hand column ‘under of the control of’ should read ‘under the control of’.
Br J Clin Pharmacol 2001; 52: 201-204.
‘Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval’.
Michael S. Gillen, Barry Miller, Philip Chaikin & Joel Morganroth
p. 202 The last sentence of the Pharmacodynamic results section should read ‘Terfenadine caused a 14.1 ms increase in QTcF, which was significantly greater (P<0.0001) than the other three treatments’.
p. 203 Table 2, column 8. The 95% CI for ebastine vs. terfenadine for mean HR (beats min−1) should be [1.44, 5.56] and [3.14, 7.26] instead of [1.5, 44.56] and [3.7, 14.26].